Longitudinal Symptom Burden and Pharmacologic Management of Catatonia in Autism With Intellectual Disability: An Observational Study
Autism Research · 2025
DOI: 10.1002/aur.3315 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Autism Research, 2025. Verfasst von Joshua Ryan Smith und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center at Village of Van…. Hauptthemen laut MEDLINE: Catatonia, Intellectual Disability, Autistic Disorder. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIDCD NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Catatonia is a highly morbid psychomotor and affective disorder, which can affect autistic individuals with and without intellectual disability. Catatonic symptoms are treatable with pharmacotherapy and electroconvulsive therapy, but the longitudinal effectiveness of these treatments in autistic individuals has not been described. We conducted a prospective observational cohort study of patients with autism and co‐morbid catatonia who received outpatient care in a specialized outpatient clinic from July 1, 2021 to May 31, 2024. Data investigating pharmacologic interventions, and clinical measures including the Bush Francis Catatonia Rating Scale (BFCRS), Kanner Catatonia Severity Scale (KCS), Kanner Catatonia Examination (KCE), and Clinical Global Impression—Improvement (CGI‐I) were collected. Forty‐five autistic patients with co‐morbid catatonia were treated during the study period. The mean age was 15.6 (SD = 7.9) years [Mdn = 16.0, range 6.0–31.0]. Forty‐one patients (91.1%) met criteria for autism with co‐occurring intellectual disability. All patients received pharmacotherapy. Forty‐four (97.8%) were treated with benzodiazepines with a mean maximal daily dose of 17.4 mg (SD = 15.8) lorazepam equivalents. Thirty‐five patients (77.8%) required more than one medication class for treatment. Sixteen (35.6%) patients received electroconvulsive therapy. Fourteen patients (31.1%) attempted to taper off benzodiazepines after achieving clinical improvement during the study period; of these, 5 patients (11.1%) were successfully tapered off, and the remaining 9 (17.8%) discontinued the taper due to a return of catatonic symptoms. Statistically significant improvement was observed across all clinical domains except the KCS. However, the majority remained at least partially symptomatic over the study period. Three patients (6.7%) died over the study period. Despite clinical improvements while receiving the gold standard for psychopharmacologic management of catatonia, chronic symptoms remained for the majority of catatonia patients over the study period, and few were able to taper and discontinue benzodiazepine treatment. Notably, the open label design of this study is a limiting factor when interpreting the results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center at Village of Vanderbilt, Nashville, Tennessee, USA.
- Vanderbilt Kennedy Center, Vanderbilt University, Nashville, Tennessee, USA.
- Division of General Psychiatry, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
- Critical Illness, Brain Dysfunction and Survivorship Center, Center for Health Services Research, Nashville, Tennessee, USA.
- Geriatric Research, Education, and Clinical Center Service, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee, USA.
ORCID-Profile: Joshua Ryan Smith, Seri Lim, Snehal Bindra, Zachary J Williams, Isaac Baldwin, Jo Ellen Wilson, D Catherine Fuchs, James Luccarelli
Förderung
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- NIDCD NIH HHS
- NIGMS NIH HHS
- Vanderbilt University Medical Center Bixler-Johnson-Mayes Endowed Chair
- NCATS NIH HHS
- NICHD NIH HHS
- National Institute of General Medical Sciences
- National Institute on Deafness and Other Communication Disorders
Zitieren
APA
Smith, J. R., Lim, S., Bindra, S., Marler, S., Rajah, B., Williams, Z. J., Baldwin, I., Hossain, N., Wilson, J. E., Fuchs, D. C., & Luccarelli, J. (2025). Longitudinal Symptom Burden and Pharmacologic Management of Catatonia in Autism With Intellectual Disability: An Observational Study. Autism Research. https://doi.org/10.1002/aur.3315
Vancouver
Smith JR, Lim S, Bindra S, Marler S, Rajah B, Williams ZJ, et al. Longitudinal Symptom Burden and Pharmacologic Management of Catatonia in Autism With Intellectual Disability: An Observational Study. Autism Research. 2025. doi:10.1002/aur.3315
BibTeX
@article{Smith2025,
author = {Smith, Joshua Ryan and Lim, Seri and Bindra, Snehal and Marler, Sarah and Rajah, Bavani and Williams, Zachary J and Baldwin, Isaac and Hossain, Nausheen and Wilson, Jo Ellen and Fuchs, D Catherine and Luccarelli, James},
title = {Longitudinal Symptom Burden and Pharmacologic Management of Catatonia in Autism With Intellectual Disability: An Observational Study},
journal = {Autism Research},
year = {2025},
doi = {10.1002/aur.3315}
}
EUVIMED